XPH ETF — SPDR® S&P Pharmaceuticals ETF

SPDR® S&P Pharmaceuticals ETF (XPH)

Updated October 16, 2026.

XPH is an ETF. its distribution rate is 0.27%, its trailing-12-month yield is 0.44%, its expense ratio is 0.35%. Dividend Vision Distribution Safety Score™ is 48/100 (Caution). Total return is 452.4% over the past 20.3 years, 335.5 points behind SPY at 787.9%.

SPDR® S&P Pharmaceuticals ETF is an ETF that tracks the S&P Pharmaceuticals Select Industry Index, holding a representative sample of pharmaceutical companies within the broader U.S. stock market. The fund carries a very modest current distribution rate, makes quarterly distributions, and charges an expense ratio of 0.35%. It appeals primarily to healthcare-focused equity investors seeking sector exposure rather than income-oriented investors.

XPH performance versus SPY

Price and return data through 2026-10-16.

Total return is 452.4% over the past 20.3 years, 335.5 points behind SPY at 787.9%. Over the past year its total return — price change plus distributions reinvested — is 29.4%. Its deepest 1-year drawdown was 16.4%.

XPH key facts

Distribution Safety Score™

48 · Caution

Safety-Adjusted Yield

0.13%

Issuer

State Street

Asset type

ETF

Asset class

Equity

Inception date

06/19/2006

Expense ratio

0.35%

Distribution rate

0.27%

Distribution frequency

Quarterly

Trailing yield

0.44%

Last close

$61.84 (as of 2026-10-16)

AUM

$487,141,137

Average volume

241462.0

Dividend

$0.042

Ex-dividend date

09/21/2026

Payment date

09/23/2026

Beta

0.68

How Dividend Vision calculates yield and returns

Distribution rate (0.27%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (0.44%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: State Street; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

XPH risks and drawbacks

XPH's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are quarterly, so cash flow is lumpy versus a monthly fund. Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 16.4%.

Who may consider XPH — and who may not

It is a weaker fit for investors who need monthly cash flow (XPH pays quarterly); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on XPH

• All tickers starting with X

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions

More securities from State Street.